Konstantin Konstantinov
Director/Board Member chez REPLIGEN CORPORATION
Fortune : 224 382 $ au 31/03/2024
Profil
Konstantin Konstantinov is an Independent Director at Repligen Corp., an Operating Partner at Flagship Pioneering, and the Chief Technology Officer at Ring Therapeutics, Inc. He previously worked as the Vice President at Genzyme Corp., Head of Process Sciences at Bayer Healthcare Pharmaceuticals LLC, and Senior VP of Manufacturing & Process Sciences at Codiak BioSciences, Inc. Konstantinov holds a doctorate degree from Osaka University and undergraduate and graduate degrees from Technical University of Sofia.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
REPLIGEN CORPORATION
0,00% | 18/03/2024 | 1 220 ( 0,00% ) | 224 382 $ | 31/03/2024 |
Postes actifs de Konstantin Konstantinov
| Sociétés | Poste | Début |
|---|---|---|
| REPLIGEN CORPORATION | Director/Board Member | 26/05/2022 |
Ring Therapeutics, Inc.
 Ring Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ring Therapeutics, Inc. engages in the development of a gene therapy platform. Its Anellovector platform provides tissue specifities benefitting from the inherent diversity of tropism afforded by the commensal virome. The company was founded in 2000 and is headquartered in Cambridge, MA. | Chief Tech/Sci/R&D Officer | 07/06/2023 |
Flagship Pioneering
 Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Private Equity Investor | 07/06/2023 |
Anciens postes connus de Konstantin Konstantinov
| Sociétés | Poste | Fin |
|---|---|---|
| Bayer Healthcare Pharmaceuticals LLC | Corporate Officer/Principal | 01/01/2007 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
| CODIAK BIOSCIENCES | Chief Tech/Sci/R&D Officer | - |
Formation de Konstantin Konstantinov
| Osaka University | Doctorate Degree |
| Technical University of Sofia | Graduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| REPLIGEN CORPORATION | Health Technology |
| Entreprise privées | 5 |
|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Flagship Pioneering
Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Finance |
| Bayer Healthcare Pharmaceuticals LLC | |
Codiak BioSciences, Inc.
 Codiak BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Codiak BioSciences, Inc. engages in the development and manufacturing of exosomes. It engages in harnessing exosomes, therapeutic applications, diagnostic applications, and proprietary production. The firm develops engEx Platform, a proprietary and versatile exosome engineering and manufacturing platform, to expand upon the innate properties of exosomes to design novel exosome therapeutics. Codiak BioSciences was founded by Douglas E. William, Raghu Kalluri, and Eric S. Lander in 2015 and is headquartered in Cambridge, MA. | Health Technology |
Ring Therapeutics, Inc.
Ring Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ring Therapeutics, Inc. engages in the development of a gene therapy platform. Its Anellovector platform provides tissue specifities benefitting from the inherent diversity of tropism afforded by the commensal virome. The company was founded in 2000 and is headquartered in Cambridge, MA. | Health Technology |
